Oncothyreon Inc. (NASDAQ: ONTY) is doing what appears to be a small secondary stock offering to raise capital, but it is one of those offerings where the price comes at a steep discount to the…
Here is the sad fact about health care: there is often little relationship between what is spent on medical care and the results. Nations like the US, which not only have huge health care…
Community Health Systems, Inc. (NYSE: CYH) was one we flagged over the weekend for “the biggest analyst calls of the week” due to its move early last week and then again in the after-hours…
The drug sector has become rather boring and investors already know all about the ongoing patent expiration threats that loom in the industry. The good news is that the drug sector does still offer…
Amarin Inc. (NASDAQ: AMRN) just went off the charts, literally. The company reported very solid Phase III study results this morning and the stock is now up almost tenfold from its lows seen in…
The idea of compensating donors of vital organs, which strikes many as morally repugnant, is gaining acceptance among some parts of the medical community which has grown frustrated at watching thousands of patients die…
Biotech is becoming the ever-shrinking stock sector. It is almost weekly now that a new biotech acquisition is announced. Big Pharma in the United States and large drugmakers internationally are all interested in acquiring the next latest…
We have been featuring many REITs for their high dividends on our daily “Dividend Watch” pieces. One sector which has not been tabulated and screened is the ability to make dividend payments off of the…
Curis Inc. (NASDAQ: CRIS) is not exactly a household name, even when it comes to the land of biotech investors. The company has come under focus today after announcing that it is presenting data…
Cubist Pharmaceuticals Inc. (NASDAQ: CBST) is going to be back in favor now that it has settled a key patent case against Teva Pharmaceutical Industries Limited (NASDAQ: TEVA). The company announced that it will grant…
VIVUS Inc. (NASDAQ: VVUS) was recently shown as one of our five biotechs with 50% upside and news this morning is showing why VIVUS may be one of the only possible diet drugs which…
Earlier this week, we highlighted Dendreon Corporation (NASDAQ: DNDN) as one of five biotechs with 50% implied upside. A new report is out from Canaccord Genuity that has figures which could imply even more…
When we first covered K-V Pharmaceutical Co. (NYSE: KV-A) for its Makena drug market exclusivity to prevent premature birth, we knew this was going to be a home run. But earlier in March when…
Biotech is about to become even less of a diversified sector due to mergers and acquisitions. Genzyme Corporation (NASDAQ: GENZ) and Cephalon Inc. (NASDAQ: CEPH) will end up accounting for about $30 billion in…
The proposed buyout of Genzyme Corporation (NASDAQ: GENZ) by Sanofi-Aventis (NYSE: SNY) should close this week. We are about to get a new Genzyme security on the market and that will be the Contingent…